product name Dexamethasone Acetate
Description: Dexamethasone Acetate (also known as NSC 39471) is the 21-acetoxy (ester) form of Dexamethasone, it is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone has anti-inflammatory and immunosuppressant effects. It is 25-fold more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.
References: Neurosci Lett. 2003 Jun 26;344(2):112-6; J Physiol. 2003 Feb 15;547(Pt 1):61-6.
434.5
Formula
C24H31FO6
CAS No.
1177-87-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 87 mg/mL (200.2 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (46.0 mM)
Solubility (In vivo)
Synonyms
NSC 39471
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395758
| In Vitro |
In vitro activity: Dexamethasone inhibits COX-2 mRNA expression induced by IL-1 in human articular chondrocytes. Dexamethasone suppresses the cyclooxygenase-2 induction by tumor necrosis factor α (TNFα) with an IC50 of 1 nM in MC3T3-E1 cells. Dexamethasone binds to the glucocorticoid receptor and then to the glucocorticoid response element. Dexamethasone (10 μM) induces osteoblastic differentiation of rat bone marrow stromal cell cultures with elevated mRNA expression of alkaline phosphatase osteopontin, bone sialoprotein, and osteocalcin. Dexamethasone (5 μM) treatment decreases proliferation of adult hippocampal neural progenitor cells and SRE-driven gene expression. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Dexamethasone (2 mg/kg) reduces the number of the BrdU-labeled hepatocytes by 80% in male Fischer F344 rats. Dexamethasone (2 mg/kg) pretreatment suppresses the expression of both TNF and IL-6 after partial hepatectomy and significantly reduces the proliferative response of the hepatocytes in male Fischer F344 rats. Dexamethasone also severely diminishes the induction and expansion of oval cells induced by the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) protocol but does not have any effect on the proliferation of the bile duct cells stimulated by bile duct ligation. Dexamethasone (100 μg/kg) produces a significant decrease 59.2% of BrdU(+) hippocampal progenitor cells in Sprague–Dawley rats. Dexamethasone (100 μg/kg) decreases ERK activation in granule cell layer in Sprague–Dawley rats. |
| Animal model | Sprague-Dawley rats |
| Formulation & Dosage | Dissolved in saline; 100 μg/kg; i.p. injection |
| References | J Rheumatol. 1999 Jun;26(6):1366-73; Hepatology. 1998 Aug;28(2):423-9. |
Related Posts
product name Dexamethasone Acetate
Description: Dexamethasone Acetate (also known as NSC 39471) is the 21-acetoxy (ester) form of Dexamethasone, it is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone has anti-inflammatory and immunosuppressant effects. It is 25-fold more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect.
References: Neurosci Lett. 2003 Jun 26;344(2):112-6; J Physiol. 2003 Feb 15;547(Pt 1):61-6.
434.5
Formula
C24H31FO6
CAS No.
1177-87-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 87 mg/mL (200.2 mM)
Water: <1 mg/mL
Ethanol: 20 mg/mL (46.0 mM)
Solubility (In vivo)
Synonyms
NSC 39471
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19395758
| In Vitro |
In vitro activity: Dexamethasone inhibits COX-2 mRNA expression induced by IL-1 in human articular chondrocytes. Dexamethasone suppresses the cyclooxygenase-2 induction by tumor necrosis factor α (TNFα) with an IC50 of 1 nM in MC3T3-E1 cells. Dexamethasone binds to the glucocorticoid receptor and then to the glucocorticoid response element. Dexamethasone (10 μM) induces osteoblastic differentiation of rat bone marrow stromal cell cultures with elevated mRNA expression of alkaline phosphatase osteopontin, bone sialoprotein, and osteocalcin. Dexamethasone (5 μM) treatment decreases proliferation of adult hippocampal neural progenitor cells and SRE-driven gene expression. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Dexamethasone (2 mg/kg) reduces the number of the BrdU-labeled hepatocytes by 80% in male Fischer F344 rats. Dexamethasone (2 mg/kg) pretreatment suppresses the expression of both TNF and IL-6 after partial hepatectomy and significantly reduces the proliferative response of the hepatocytes in male Fischer F344 rats. Dexamethasone also severely diminishes the induction and expansion of oval cells induced by the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) protocol but does not have any effect on the proliferation of the bile duct cells stimulated by bile duct ligation. Dexamethasone (100 μg/kg) produces a significant decrease 59.2% of BrdU(+) hippocampal progenitor cells in Sprague–Dawley rats. Dexamethasone (100 μg/kg) decreases ERK activation in granule cell layer in Sprague–Dawley rats. |
| Animal model | Sprague-Dawley rats |
| Formulation & Dosage | Dissolved in saline; 100 μg/kg; i.p. injection |
| References | J Rheumatol. 1999 Jun;26(6):1366-73; Hepatology. 1998 Aug;28(2):423-9. |